The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer

The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer

Purpose: DNA demethylating agents have shown clinical effectiveness in hematological and solid tumors. This trial tested the safety, efficacy, and treatment outcomes of decitabine-based chemotherapy or combined with immunotherapy in recurrent ovarian cancer patients. Patients and methods: Fifty-five...

Full description

Bibliographic Details
Main Authors:	Yan Zhang, Qian Mei, Yang Liu, Xiang Li, Malcolm V. Brock, Meixia Chen, Liang Dong, Lu Shi, Yao Wang, Mingzhou Guo, Jing Nie, Weidong Han
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-09-01
Series:	OncoImmunology
Subjects:	cik therapy decitabine epigenetic therapy platinum sensitivity recurrent ovarian cancer
Online Access:	http://dx.doi.org/10.1080/2162402X.2017.1323619

Similar Items

A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis
by: Yuanzhi Liu, et al.
Published: (2022-11-01)

Surgical treatment of recurrent ovarian cancer: A review
by: Omar A. Egenov, et al.
Published: (2021-12-01)

Introduction to managing patients with recurrent ovarian cancer
by: Hani Gabra
Published: (2014-12-01)

A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations
by: Kazuho Nakanishi, et al.
Published: (2023-05-01)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
by: Eva María Guerra Alía, et al.
Published: (2019-06-01)

A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia
by: Lilit Harutyunyan, et al.
Published: (2024-03-01)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
by: Patrick J. Stiff, et al.
Published: (2023-09-01)

Progress of Surgery on Platinum-sensitive Recurrent Ovarian Cancer
by: HE Liya, et al.
Published: (2021-09-01)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
by: Xin Yan, et al.
Published: (2020-10-01)

Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance
by: Yin-Ting Chuang, et al.
Published: (2012-09-01)

Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy
by: Yen-Fu Chen, et al.
Published: (2024-01-01)

Platinum-sensitive recurrence in ovarian cancer: The role of tumor microenvironment
by: Jeremy eChien, et al.
Published: (2013-09-01)

Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS
by: Miklos Acs, et al.
Published: (2023-01-01)

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma
by: Lien Provez, et al.
Published: (2023-01-01)

Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients
by: Thomas Bartl, et al.
Published: (2021-03-01)

Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer
by: Hanieh Meteran, et al.
Published: (2024-02-01)

Comparison of the effects of olsalazine and decitabine on the expression of CDH1 and uPA genes and cytotoxicity in MDA-MB-231 breast cancer cells
by: Misagh Mohammadi Asl, et al.
Published: (2021-01-01)

The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine
by: Alicja Pawlak, et al.
Published: (2022-03-01)

Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells
by: Sonia Abou Najem, et al.
Published: (2019-11-01)

Demethylating Agents in the Treatment of Cancer
by: Paul M. Howell, Jr., et al.
Published: (2010-07-01)

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
by: Karahoca Metin, et al.
Published: (2013-02-01)

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability
by: Ganjun Yu, et al.
Published: (2022-06-01)

The current role of secondary cytoreductive surgery for recurrent ovarian cancer
by: Eelco de Bree, et al.
Published: (2022-10-01)

Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma
by: Timothy Budden, et al.
Published: (2018-01-01)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
by: Wonkyo Shin, et al.
Published: (2018-05-01)

Pattern of Recurrence After Platinum-Containing Definitive Therapy and Efficacy of Salvage Treatment for Recurrence in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Tetsuro Wakasugi, et al.
Published: (2022-07-01)

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
by: Briot T, et al.
Published: (2017-11-01)

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
by: María Jesús Rubio Pérez
Published: (2017-05-01)

Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2’-deoxycytidine, DAC)
by: Richard L Momparler
Published: (2013-07-01)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
by: Denise Maravalle, et al.
Published: (2022-05-01)

The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients
by: Osnat Elyashiv, et al.
Published: (2024-02-01)

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes
by: Seungyoun Kim, et al.
Published: (2021-12-01)

Methylomic Signatures of High Grade Serous Ovarian Cancer
by: Horacio Cardenas, et al.
Published: (2021-11-01)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
by: Jehad Almasri, et al.
Published: (2018-09-01)

The role of topotecan in prolongation of platinum-free interval in patients with recurrent ovarian cancer
by: E U Moskovskaya, et al.
Published: (2014-03-01)

Hairpin-bisulfite sequencing of cells exposed to decitabine documents the process of DNA demethylation
by: Issam M Mayyas, et al.
Published: (2021-11-01)

Immunomodulatory therapy in refractory/recurrent ovarian cancer
by: Chao-Yu Chen, et al.
Published: (2015-04-01)

Pt(II)-PLGA Hybrid in a pH-Responsive Nanoparticle System Targeting Ovarian Cancer
by: Marek T. Wlodarczyk, et al.
Published: (2023-02-01)

Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study
by: Zhang J, et al.
Published: (2019-11-01)

Surgical treatment of patients with lymph node involvement in recurrent ovarian cancer: immediate and long-term results
by: O. A. Egenov, et al.
Published: (2022-04-01)